echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > 85% of patients with early multiple sclerosis have no disease progression Roche CD20 antibody latest...

    85% of patients with early multiple sclerosis have no disease progression Roche CD20 antibody latest...

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Roche announced the positive results of its CD20 antibody Ocrevus (ocrelizumab) in the treatment of patients with early multiple sclerosis (MS).


    Multiple sclerosis (MS) is a chronic autoimmune disease caused by the immune system attacking the myelin sheath that protects nerves.


    Ocrevus is a humanized monoclonal antibody targeting CD20 positive B cells.


    In the Phase 3 clinical trial called ENSEMBLE, patients who were newly diagnosed and had not yet received pre-disease modification therapy (DMT) received Ocrevus treatment.


    "All MS patients, regardless of the type of disease they have, will experience disease progression.


    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.